VJOncology is committed to improving our service to you

ELCC 2019 | Phase III real-world PACIFIC-R trial for NSCLC

VJOncology is committed to improving our service to you

Nicolas Girard

Nicolas Girard, MD, PhD, from Claude Bernard University, Lyon, France, gives an overview of the real-world Phase III PACIFIC-R trial (NCT03798535), where post-chemoradiotherapy administration of durvalumab shows promising results in patients with unresectable stage III non-small cell lung cancer (NSCLC). At the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Prof. Girard then discusses the strategies for clinical trial expansion.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter